NeuroMetrix (NSDQ:NURO) shares lost more than 4% of their value yesterday after the medical device company reported a more than 25% sales slide during the 3rd quarter.

Despite the top-line slide, NeuroMetrix managed to pare its losses by nearly 73% during the 3 months ended Sept. 30. The Waltham, Mass.-based medical device company reported losses of $716,264, or 26¢ per share, on sales of $1.3 million for quarter.

"Sensus is gaining attention among key national distribution companies who see the clinical and market potential for a non-narcotic, non-addictive pain relief option. Although the engagement process takes time, we are encouraged by our recently-announced partnerships with Diabetes Care Club and OsteoArthritis Centers of America. Our distributor pipeline is active and expanding. We continue to be focused on building a sound distribution foundation capable of accelerating Sensus revenues in 2014 and beyond," president & CEO Shai Gozani said in prepared remarks.

In July, the FDA granted 510(k) clearance to NeuroMetrix’s Sensus pain management system.

NURO shares fell 4.4% to $1.51 apiece yesterday.